이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Cumberland Pharmaceuticals 관리

관리 기준 확인 3/4

Cumberland Pharmaceuticals' CEO는 A. Kazimi, Jan1999 에 임명되었습니다 의 임기는 25.42 년입니다. 총 연간 보상은 $ 1.17M, 57.7% 로 구성됩니다. 57.7% 급여 및 42.3% 보너스(회사 주식 및 옵션 포함). 는 $ 8.83M 가치에 해당하는 회사 주식의 40.13% 직접 소유합니다. 8.83M. 경영진과 이사회의 평균 재임 기간은 각각 6.5 년과 11.1 년입니다.

주요 정보

A. Kazimi

최고 경영자

US$1.2m

총 보상

CEO 급여 비율	57.7%
CEO 임기	25.4yrs
CEO 소유권	40.1%
경영진 평균 재임 기간	6.5yrs
이사회 평균 재임 기간	11.1yrs

최근 관리 업데이트

Recent updates

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Mar 07

Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares

Jan 09

Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S

Oct 02

Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?

Nov 09

We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation

Apr 21

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?

Feb 13

One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts

Nov 19

Cumberland Pharmaceuticals Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

CEO 보상 분석

A. Kazimi 의 보수는 Cumberland Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$1m	US$675k	-US$6m
Sep 30 2023	n/a	n/a	-US$2m
Jun 30 2023	n/a	n/a	-US$2m
Mar 31 2023	n/a	n/a	-US$4m
Dec 31 2022	US$1m	US$635k	-US$6m
Sep 30 2022	n/a	n/a	-US$7m
Jun 30 2022	n/a	n/a	-US$9m
Mar 31 2022	n/a	n/a	-US$7m
Dec 31 2021	US$1m	US$610k	-US$6m
Sep 30 2021	n/a	n/a	-US$3m
Jun 30 2021	n/a	n/a	-US$3m
Mar 31 2021	n/a	n/a	-US$5m
Dec 31 2020	US$1m	US$590k	-US$7m
Sep 30 2020	n/a	n/a	-US$8m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$10m
Dec 31 2019	US$1m	US$567k	-US$9m
Sep 30 2019	n/a	n/a	-US$8m
Jun 30 2019	n/a	n/a	-US$6m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$1m	US$545k	-US$11m
Sep 30 2018	n/a	n/a	-US$6m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$9m
Dec 31 2017	US$1m	US$523k	-US$8m

보상 대 시장: A. 의 총 보상 ($USD 1.17M )은 US 시장( $USD 683.56K ).

보상과 수익: A. 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

A. Kazimi (66 yo)

25.4yrs

테뉴어

US$1,169,530

보상

Mr. A. J. Kazimi, MBA, founded Cumberland Pharmaceuticals Inc. in 1999 and has been its Chairman and Chief Executive Officer since 1999. Mr. Kazimi serves as the President of Cumberland Pharmaceuticals Inc...

리더십 팀

이름	위치	테뉴어	보상	소유권
A. Kazimi	Founder	25.4yrs	US$1.17m	40.13% $ 8.8m
John Hamm	VP & CFO	3.1yrs	US$282.32k	0.18% $ 40.3k
James Herman	Executive VP of National Accounts & Chief Compliance Officer	7.7yrs	US$400.15k	0.27% $ 59.3k
Chris Bitterman	Vice President of Sales & Marketing	no data	US$316.29k	0.033% $ 7.3k
Todd Anthony	Vice President of Organizational Development	no data	US$330.85k	0.12% $ 25.3k
Jean Marstiller	Senior VP of Administrative Services & Corporate Secretary	no data	US$298.01k	데이터 없음
Adam Mostafa	Managing Director	5.3yrs	데이터 없음	데이터 없음
Erin Gull	Senior Corporate Relations Associate	no data	데이터 없음	데이터 없음

6.5yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 관리: CPIX 의 관리팀은 노련하고 경험 (평균 재직 기간 6.5 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
A. Kazimi	Founder	25.4yrs	US$1.17m	40.13% $ 8.8m
Joseph Williams	Member of Pharmaceutical Advisory Board	no data	데이터 없음	데이터 없음
Joseph Galante	Independent Director	5.8yrs	US$61.20k	0.42% $ 92.0k
Robert Roberts	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Gordon Bernard	Chairman of Medical Advisory Board & Independent Director	14.4yrs	US$98.00k	데이터 없음
J. Hix	Member of Pharmaceutical Advisory Board	no data	US$233.65k	데이터 없음
Martin Brown	Director	1.9yrs	US$50.00k	0.042% $ 9.3k
David Warrell	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Timothy Meakin	Member of Pharmaceutical Advisory Board	no data	데이터 없음	데이터 없음
Ben deBoisblanc	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Caroline Young	Independent Director	7.8yrs	US$61.20k	0.19% $ 41.4k
James Jones	Independent Director	14.4yrs	US$60.20k	데이터 없음

11.1yrs

평균 재임 기간

72yo

평균 연령

경험이 풍부한 이사회: CPIX 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 11.1 년).

Cumberland Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 23, 2024

Cumberland Pharmaceuticals Inc. Announces Demise of Joey A. Jacobs, Member of Board of Directors

Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of Directors

Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of Directors

Cumberland Pharmaceuticals Inc. Announces Executive Changes

Insufficient new directors

Recent updates

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2023)

Cumberland Pharmaceuticals Inc. to Report Q1, 2024 Results on May 07, 2024

Cumberland Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $5.8 million.

New minor risk - Share price stability

Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 23, 2024

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Full year 2023 earnings released: US$0.44 loss per share (vs US$0.38 loss in FY 2022)

Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 05, 2024

Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.073 loss per share (vs US$0.028 loss in 3Q 2022)

Cumberland Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 07, 2023

Cumberland Pharmaceuticals Inc. Announces New Antimicrobial Agents and Chemotherapy Detaining the Results of the First Clinical Study Investigating the Safety and Pharmacokinetics of Vibativ®? Injection in Children 2 to 17 Years of Age

New minor risk - Share price stability

Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Second quarter 2023 earnings released: EPS: US$0.061 (vs US$0.091 loss in 2Q 2022)

Cumberland Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 08, 2023

Cumberland Pharmaceuticals Inc. Announces the Publication of Positive Results from Clinical Study Investigating the Safety and Pharmacokinetics of Caldolor in Newborn Infants, Published in the Journal Pediatric Drugs

Cumberland Pharmaceuticals Inc. Announces FDA Clearance of IND for New Treatment of Idiopathic Pulmonary Fibrosis

U.S. Food and Drug Administration Approves Cumberland Pharmaceuticals Inc.'s Expanded Lab Labulation for Caldolor

First quarter 2023 earnings released: EPS: US$0.013 (vs US$0.094 loss in 1Q 2022)

Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?

Full year 2022 earnings released: US$0.38 loss per share (vs US$0.37 loss in FY 2021)

Cumberland Pharmaceuticals Inc. Announces Demise of Joey A. Jacobs, Member of Board of Directors

Cumberland Pharmaceuticals Inc. Announces Approval of Supplemental New Drug Application from U.S. Food and Drug Administration

Third quarter 2022 earnings released: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021)

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Cumberland Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.091 loss per share (vs US$0.049 profit in 2Q 2021)

Cumberland Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 09, 2022

Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of Directors

Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)

Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of Directors

Cumberland Pharmaceuticals Inc. Announces Executive Changes

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cumberland Pharmaceuticals Inc. to Report Q1, 2022 Results on May 10, 2022

Insufficient new directors

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Tabuk and Cumberland Partner to Bring Innovative Antibiotic with Life-Saving Potential to Middle East

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2021 Results on Mar 08, 2022

Now 22% undervalued

Cumberland Pharmaceuticals Inc. (NasdaqGS:CPIX) acquired SANCUSO from Kyowa Kirin, Inc. for $17 million.

Checking In On Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. Receives FDA Approval for Expanded Labeling for Caldolor®

Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.083 loss in 3Q 2020)

Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?

Consensus forecasts updated

Second quarter 2021 earnings released: EPS US$0.049 (vs US$0.11 loss in 2Q 2020)

Cumberland Pharmaceuticals Inc.(NasdaqGS:CPIX) dropped from Russell Microcap Growth Index

Cumberland Pharmaceuticals Inc. Releases a Series of Case Reports Describing the Effectiveness of Vibativ® (Telavancin) in Treating Secondary Bacterial Infections in COVID-19 Patients

Consensus EPS estimates increase to -US$0.18

We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation

Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 27, 2021

Full year 2020 earnings released: US$0.43 loss per share (vs US$0.23 loss in FY 2019)

Revenue beats expectations

Cumberland Pharmaceuticals Inc. to Report Q4, 2020 Results on Mar 09, 2021

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?

New 90-day high: US$3.31

New 90-day high: US$3.22

Analysts update estimates

One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts

Cumberland Pharmaceuticals Inc. Announces the Launch of Reditrex® (Methotrexate) Injection

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.083 loss per share

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.083 loss per share